Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis.
CITATION STYLE
Peitz, J., & Horneff, G. (2015, February 18). Treatment of systemic-onset juvenile arthritis with canakinumab. Open Access Rheumatology: Research and Reviews. Dove Medical Press Ltd. https://doi.org/10.2147/OARRR.S54215
Mendeley helps you to discover research relevant for your work.